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 ABSTRACT 
Rotavirus infects mature enterocytes of the small intestine of young children and 
cause gastroenteritis, leading to approximately 500 000 deaths annually 
worldwide, 85 % of which occur in the developing world. The main objectives 
of the thesis were to investigate host genetic factors leading to differential 
susceptibility to rotavirus infections and to develop an antibody-based oral 
therapy against the infections.  
Reduced TLR3 expression was previously suggested to be associated with 
susceptibility to rotavirus infections. In Paper I, we thus investigated rotavirus-
specific IgG antibody responses from individuals (IgA competent or deficient) 
using two TLR3 SNPs (rs3775291 and rs5743305). We concluded that these two 
polymorphisms were associated with elevated IgG titers in IgA deficient, but not 
in IgA competent individuals. In addition, recent in vitro studies have suggested 
that HBGAs (H type 1 and Lewis antigens) serve as putative receptors for 
rotavirus VP8*, and play a role in susceptibility to infections in vivo. In Paper 
II, we therefore studied the effect of SNPs in the FUT2 (rs601338) and FUT3 
genes (rs28362459, rs3894326, rs812936 and rs778986) on the serum IgG 
antibody titers and neutralizing antibody levels to rotavirus P[6] and P[8]. The 
rotavirus specific serum IgG levels and neutralizing antibody titers to the Wa 
strain (P[8]) of rotavirus were significantly higher in secretors (individuals with 
an intact FUT2), suggesting that secretor individuals, expressing the Lewis b 
antigen, are more prone to rotavirus (P[8]) infections than non-secretors.  
We have recently developed an antibody-based therapy against rotavirus, which 
may confer safe, immediate and efficient viral neutralization and protection. 
Probiotic bacteria represent an attractive delivery system for antibody fragments 
and other proteins in the gastrointestinal tract. In Paper III, the combination 
therapy including engineered L. rhamnosus GG expressing IgG binding domains 
of protein G and HBC was shown to be more effective in reducing the 
prevalence, severity, and duration of diarrhea in a mouse pup model of RRV 
infection in comparison to HBC alone or a combination of wild-type L. 
rhamnosus GG and HBC. In Paper IV, we developed vectors for co-production 
of two VHHs: ARP1 and ARP3, by engineered L. paracasei BL23. Both 
fragments (secreted or anchored) were shown to bind to a broad range of human 
rotavirus serotypes in vitro. In Paper V, we have shown that the fusion of the 
mouse IgG1 Fc to ARP1 (Fc-ARP1) confers a markedly increased protection 
against rotavirus in a neonatal mouse model of rotavirus-induced diarrhea, 
suggesting a role for Fc-mediated neutralization of rotavirus. These antibody-
based treatments could be further developed and used as an alternative or 
complement to current vaccines.  
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1. INTRODUCTION 
1.1. ROTAVIRUS BIOLOGY 
Rotavirus is a non-enveloped double stranded RNA (dsRNA) virus within 
Reoviridae family. Rotaviruses are classified into seven groups (A to G) on the 
basis of their distinct antigenic and genetic properties, with group A rotaviruses 
being the main cause of infection in humans (1). The mature and infectious 
rotavirus particle is approximately 100 nm in diameter, and composed of a three-
layered icosahedral protein capsid surrounding the genome (Figure 1) (2, 3).  
 
Figure 1. The schematic representation of a rotavirus virion (3). Reprinted with 
the permission from Nature Publishing Group.  
The rotavirus genome contains 11 segmented dsRNA, encoding 12 viral proteins 
characterized in two categories: structural (VP1-4, VP6, and VP7) and non-
structural (NSP1-6) proteins. The inner layer of the virion is composed of the 
scaffolding core protein VP2, the RNA-dependent RNA polymerase VP1, the 
RNA capping enzyme VP3, and genomic RNA. The intermediate layer is made 
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of VP6, which is the most abundant and highly conserved protein, and also the 
group and subgroup specific rotavirus antigen, used for classification purposes. 
The outer layer is composed of VP4 and VP7 proteins which elicit neutralizing 
antibodies and form the basis of the current dual classification of group A 
rotavirus into G- (glycoprotein VP7) and P- (protease-sensitive protein VP4) 
types (Figure 1).     
The outermost layer of rotavirus virion is lost during the cell entry, yielding 
transcriptionally active double layered rotavirus particles (DLPs) (Figure 2) (4). 
DLPs are responsible for transcription of viral mRNAs. The plus strand RNA is 
extruded from DLPs through channel and translated into viral proteins. The 
synthesized rotavirus NSP proteins mediate replication of rotavirus (Figure 2).    
 
Figure 2. The rotavirus replication cycle (4). Reprinted with the permission from 
Elsevier.  
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The NSP1 protein is engaged in inhibition of IFN- responses, NSP2 is required 
for dsRNA synthesis, and NSP3 is essential for translational regulation and 
inhibition of host protein synthesis. The viral enterotoxin NSP4 increases the 
concentration of Ca
2+
, which disrupts the cytoskeleton of microvilli and the 
cellular homeostasis of the host. NSP4 is the major contributing factor to 
electrolyte and fluid malabsorption causing diarrhea. In addition, NSP5 interacts 
with NSP2 to form cytoplasmic structures known as viroplasms, inside of which 
RNA replication and morphogenesis of new viral particles take place. NSP6 
interacts with NSP5 in the viroplasms, but its function is unknown, being not 
coded by all rotavirus strains (3, 4).    
1.2. PATHOGENESIS OF ROTAVIRUS INFECTIONS AND 
EPIDEMIOLOGY STUDIES  
Rotavirus is the most crucial pediatric pathogen, infecting infants and children 
younger than 5 years of age, and is associated to several clinical symptoms 
including acute diarrhea, nausea, abdominal pain, fever, and in some cases, 
vomiting.  
The virus infects the mature enterocytes of the small intestine (2). The apical villi 
undergo atrophy and crypt hyperplasia, leading to nutrient malabsorption and 
increased secretion, hence diarrhea. These series of events lead to intestinal tract 
infection, also referred to as acute gastroenteritis.  
The rotavirus infections cause approximately 500 000 annual deaths worldwide, 
85 % of which occur in low and middle income countries. Based on a recent 
report of World Health Organization (WHO), rotavirus induced acute 
gastroenteritis caused mortality constitutes 5 % of all child deaths (5). In 
addition, an annual approximate of 2 million hospitalizations and 25 million 
clinic visits, caused by rotavirus induced gastroenteritis, has been correlated to 
significant economic burden worldwide, especially in the developing world (6).  
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1.3. DISTRIBUTION OF ROTAVIRUS GENOTYPES 
Group A rotavirus strains are classified in 23 G types and 31 P types known so 
far. The global distribution of common rotavirus G/P type combinations is as 
follows: G1 P[8] (31 %), G2 P[4] (19 %), G3 P[8] (10 %), G9 P[8] (6 %) and G4 
P[8] (4 %) (7). These five most common genotypes are detected in more than 85 
% of infected individuals both in Europe and America, however they account for 
only 40 % of circulating genotypes in Africa. The combinations other than 
aforementioned genotypes are called “uncommon”, and account for 20 % of all 
genotypes in the world. The frequency of uncommon rotavirus genotypes 
circulating in Europe (9 %) and America (8 %) is lower as compared to in Africa 
(35 %) (7). Remarkably, G1 P[8], the most prevalent rotavirus genotype 
circulating in Europe (33 %) and America (43 %), constitutes only 14 % of all 
circulating rotavirus genotypes in Africa (7). The diversity among strains along 
with geographical and temporal variations, and emergence of new strains 
potentially poses a challenge in the development of vaccine and other forms of 
immune therapy. In addition, current monovalent and pentavalent vaccines 
include only the P[8] genotype. Host genetic factors influence rotavirus P[8]-
specific responses, which may be associated to reduced efficacy with currently 
licensed vaccines in the developing world as compared to developed countries.    
1.4. HOST GENETIC FACTORS IN ROTAVIRUS 
INFECTIONS 
1.4.1. Cell Surface Receptors 
The outer capsid protein VP4 mediates rotavirus attachment and viral entry to 
mature enterocytes by its trypsin activated glycan binding domain, also referred 
to as VP8* (Figure 2) (8). Earlier in vitro studies showed that the infection of 
the host cell by some animal rotavirus strains is dependent on sialic acid residues 
(9). Subsequent studies showed that the requirement of sialic acid is associated 
with the P genotypes but independent of the host origin of the strains (10). 
Animal and human rotaviruses with P[1], P[2], P[3], and P[7] genotypes 
recognize terminal sialic acid residues of carbohydrates on the host cell surface 
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(referred to as sialidase-sensitive) (10, 11), while many other animal and human 
rotaviruses (with common genotypes of P[4], P[6], and P[8]) are sialidase-
insensitive. The sialidase-insensitive strains might recognize internal sialic acid 
residues (12), but the role of subterminal sialic acid in infection with rotaviruses 
has not been demonstrated. The lack of a defined receptor for the sialidase-
insensitive rotaviruses has prompted further studies.  
The type 1 chain histo-blood group antigens (HBGAs) are expressed in several 
cell types including intestinal epithelial cells, and found in biological fluids such 
as blood, saliva, and milk (13). They have been previously identified as cell 
attachment and susceptibility factors for norovirus (14) and Helicobacter pylori 
(15) infections. A recent key discovery by Hu et al. shows that A-type HBGAs 
bind to human rotavirus VP8*, and this binding site is similar to the terminal 
sialic acid attachment domain on animal rotavirus VP8* (16). In addition, recent 
in vitro studies demonstrate that human rotavirus VP8* recognizes HBGAs in a 
P-genotype specific manner (10, 17), suggesting a genetic predisposition for 
susceptibility to distinct rotavirus strains.    
The α-1,2-fucosyltransferase enzyme, encoded by secretor (FUT2) gene, 
converts the type 1 chain precursor to H type 1 antigen (Figure 3). In addition, 
α-1,3-fucosyltransferase enzyme, encoded by Lewis (FUT3) gene, converts H 
type 1 antigen to Lewis b (Le
b
), and type 1 chain precursor to Lewis a (Le
a
). The 
single nucleotide polymorphisms (SNPs) in FUT2 and FUT3 genes are thus 
associated with distinct expression patterns of HBGAs, determining genetic 
variability between populations. While the prevalence of a FUT2 SNP 
(rs601338), causing a non-secretor phenotype, is  approximately 30 % in the 
Caucasian population (18, 19), it is presented in approximately 65 % in south 
Africans (20). In addition, the four SNPs of the FUT3 gene (rs28362459, 
rs3894326, rs812936 and rs778986) have previously been shown to be 
associated with a Lewis negative phenotype (21), being 4-6 % in Caucasian vs. 
22- 32 % in African populations (21-23).  
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Figure 3. The synthesis of type 1 HBGAs mediated by the FUT2 and FUT3 
enzymes rendering Secretor (Se) and Lewis (Le) phenotypes (Paper II). 
The rotavirus strains of P[4] and P[8] genotypes can bind to Lewis b and H type 
1 blood group antigens, while P[6] rotavirus strains can only bind to the H type 1 
antigen (10). The secretor (FUT2) gene, mediating the expression of H type 1 
and Lewis b antigens, have been proposed as susceptibility factors to rotavirus 
(of P[8] genotype) infections in a recent study in vivo (24). The resistance to P[8] 
rotavirus infections through non-secretor phenotype might clarify the reduction 
in efficacy of current P[8]-based vaccines used in the developing world 
including sub-Saharan Africa.  
1.4.2. Intracellular Receptors  
Once rotavirus enters into the small intestinal cell, the viral transcription 
machinery is consecutively activated to produce viral components including viral 
nucleic acids, of which intracellular receptors sense and induce antiviral innate 
immune responses (Figure 4).  
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Figure 4. Rotavirus interactions with innate signaling pathways (25). Open 
access for reprinting, PLOS Publishing Group.  
Toll-like receptors (TLRs), belonging to the pattern recognition receptor (PRR) 
family, are expressed in intestinal epithelial cells (IECs) in a polarized pattern 
(26). Each member of the TLR family is specialized in recognition of various 
ligands with distinct pathogen-associated molecular patterns (PAMPs) (27). 
While some TLRs are present at the cell surface, others including TLR3, sensing 
dsRNA, are located inside the cell at the endosomes. TLR3 activation further 
engages TRIF adaptor molecules in the stimulation of nuclear mediators such as 
NF-κβ, IRF3, CREB and AP1 to induce type I (IFN-/β) and type III (IFN-λ) 
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IFNs, and other cytokines (TNF, IL-1β) or chemokine (IL-8) expression (27-30). 
In addition, melanoma differentiation-associated protein 5 (MDA5) and retinoic 
acid-inducible gene 1 (RIG-1), being members of the RIG-1-like receptor (RLR) 
family within PRR family, are also involved in intracellular rotavirus sensing. 
Even though cytosolic helicases MDA5 and RIG-1 distinctly recognize viral 
dsRNAs in a length-dependent manner (31), they might also work in 
combination to induce protective IFN responses in rotavirus infected IECs (32). 
Over 100 single nucleotide polymorphisms (SNPs) have been identified in the 
human TLR3 gene, some of which are predicted to be damaging, and associated 
with susceptibility to selected viral infections. According to PolyPhen/SIFT 
analysis, two TLR3 gene polymorphisms (rs3775291 and rs5743305) cause 
nonfunctional and reduced levels of TLR3, respectively. The L412F (rs3775291) 
SNP is associated with susceptibility to herpes simplex virus (HSV-type 1) (33), 
tick-borne encephalitis virus (TBEV) (34) and measles virus (35) infections in 
humans. Additionally, the rs5743305 promoter variant shows lower measles-
specific antibody titers in response to vaccination (35).  
A recent study by Pott et al. shows that the age-dependent predisposition to 
rotavirus infections might be due to the low expression of TLR3 in young 
humans and neonatal mice (36). Additionally, adult mice with a targeted 
inactivation in the TLR3 gene show increased level of rotaviral shedding (36). 
The absence of intact TLR3 signaling might cause viral pathogenesis and 
development of rotavirus gastroenteritis.  
1.5. IMMUNITY TO ROTAVIRUS INFECTIONS 
1.5.1. Humoral Immunity 
Early studies on natural rotavirus infection in healthy children suggest that serum 
anti-rotavirus antibodies, especially immunoglobulin A (IgA), correlates well 
with protection from rotavirus infections, and both symptomatic and 
asymptomatic infections result in similar protection levels (37). Mucosal 
immunity also seems to play a crucial role as the presence of high levels of anti-
rotavirus IgA antibodies in fecal samples has been strongly associated with 
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protection (38, 39).  The total serum anti-rotavirus IgA level, assessed shortly 
after infection, generally reflects intestinal IgA levels and appears to be the best 
marker of protection (40). However, gut immunity is of short term and difficult 
to measure. Remarkably, neutralizing secretory IgA antibody confers protection 
against rotavirus in an infant mouse model (41, 42). The viral neutralization 
mechanisms of secretory IgA might involve immune exclusion and intracellular 
viral inactivation during transcytosis of IgA in small intestine (41, 43). Even 
though IgA is defined as the major contributor of protection, elevated titers of 
serum anti-rotavirus IgG are detected in individuals with IgA deficiency (IgAD) 
(44, 45), with serum IgA levels lower than 0.07 grams per liter, as compared to 
healthy individuals, suggesting a compensatory protective role of IgG antibodies 
in rotavirus infections (44, 46).  
Although VP6 is an immunodominant antigen in the antibody response to human 
rotavirus infection (47), rotavirus outer capsid proteins VP4 and VP7 are crucial 
in eliciting neutralizing antibodies (48). However, some antibodies against VP6 
(49, 50), and enterotoxin NSP4 (51, 52) might also confer protection against 
rotavirus.  
1.5.2. Cell-mediated Immunity 
The contribution of cell-mediated immune response for protection against 
rotavirus infections is relatively unknown in human, but is most likely essential 
in resolution of the infection. The counts of rotavirus specific interferon gamma-
secreting CD4
+
 and CD8
+
 T lymphocytes are somewhat low in children with 
acute rotavirus induced diarrhea (53). In addition, rotavirus-specific T helper 
(TH) cells are detected in blood samples from infants after primary symptomatic 
rotavirus infection (54). Dendritic cells induce production of rotavirus specific 
TH1 cells, when infected with rotavirus in vitro (55). Furthermore, natural killer 
cells were found to be up-regulated via IL-15 induction after exposure to 
different rotavirus strains in vitro (51). 
In mice, the CD4
+
 T lymphocytes are essential for the development of the 
majority of RV-specific intestinal IgA (56). Furthermore, murine rotavirus-
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specific CD8
+
 T lymphocytes are engaged in the gradual resolution of primary 
rotavirus infection and induce partial protection against reinfection (57, 58).  
1.6. HUMAN ROTAVIRUS VACCINES  
The first rotavirus vaccine, Rotashield
TM 
(Wyeth-Lederle Vaccines), a tetravalent 
rhesus-human reassortant vaccine, was withdrawn from the market due to gut 
intussusception cases in 1999. Two new oral vaccines were subsequently 
developed and licensed in 2006. Rotateq
TM
 (Merck) is a live pentavalent bovine-
human reassortant vaccine, consisting of G1, G2, G3, G4 and P1A[8] types, as 
the representatives of co-circulating common wild-type rotavirus strains (59). 
Multivalent vaccines aim to induce a stronger and cross-neutralizing antibody 
response. However, Rotatix
TM
 (GlaxoSmithKline Biologicals), obtained from a 
clinical human isolate, is an attenuated monovalent (G1 P1A[8]) vaccine (59).  
Rotatix
TM 
and Rotateq
TM
 are included in national vaccination programs of 
several countries, and have been shown to be safe within the restricted age 
limitation in use (between 6-26 weeks of age). The Phase III trials report high 
efficiency (>85 %) in reducing severe rotavirus-induced diarrhea in developed 
countries, and a less pronounced decline in rotavirus associated mortality rates in 
developing countries (60-62). The vaccine efficacy is reduced in some areas 
especially in South Africa and Asia, where rotavirus infection is the single most 
deadly pathogen among children. Rotavirus vaccination elicits both homotypic 
and heterotypic immunity, and the protection is correlated with rotavirus specific 
serum IgA and IgG antibodies (51, 63).  
Certain risk groups should avoid vaccination, including older infants and infants 
with immunodeficiency disorders (64-68), as indicated in the contraindication 
reports from the two aforementioned companies. The safety and immunogenicity 
of vaccines on HIV infected immunosuppressed children should also be studied 
extensively (69).  
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1.7. PASSIVE ANTIBODY-BASED THERAPIES 
Passive immunization might represent an alternative treatment option for 
children with impaired immunity due to absence of protective antibodies 
(children with IgAD and CVID), with co-infections (HIV, enteric pathogens, 
etc.), malnutrion, genetic susceptibility factors (distinct HBGAs), and genetic 
defects (SNPs in genes affecting innate immune responses, i.e. TLR3, 
MDA5/RIG-1).   
Antibody-based therapies are successfully used for reducing or curing rotavirus 
induced diarrhea in human and animal models. Neutralizing monoclonal IgA 
antibodies against the VP4 protein, administered in a mouse hybridoma 
backpack tumor model for secretion onto mucosal surfaces via the normal 
epithelial transport pathway, elicit prophylactic protection in mice orally 
challenged with rotavirus (41, 50). Remarkably, IgA antibodies against double 
layer protein VP6, non-neutralizing in classical in vitro assays using non-
polarized cells, mediate protection in murine hybridoma backpack tumor model, 
but not in an orally fed mouse model (50). The monoclonal antibodies, when 
applied to the basolateral pole of polarized Caco-2 intestinal cells, can reduce 
viral replication, and suppress the loss of barrier function which is mediated by 
apical exposure of the cell monolayer to rotavirus (43). This suggests that the 
antiviral activity of antibodies depends on activation of intracellular antiviral 
mechanisms during transcytosis.   
Passively administered antibodies might use distinct mechanisms of 
neutralization. Monoclonal antibodies against VP4 and VP7 have been shown to 
prevent rotavirus attachment (48) and viral decapsidation (70), respectively. 
Antibodies against VP6 antibodies were shown to inhibit genome transcription 
and viral transcription in vitro (71).  
In addition to their antigen blocking activity, antibodies, depending on their 
origin, are able to induce or suppress immune responses in cells through Fc/Fc 
receptor interactions, by binding to Fc gamma receptor (FcR), neonatal Fc 
receptor (FcRn) or cytosolic Fc receptor tripartite-motif containing protein 21 
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(TRIM21). Based on the level of infection, one or more Fc receptor type(s) may 
be activated, causing different intracellular effector functions. 
Several studies have shown that oral administration of hyperimmune polyclonal 
bovine colostrum or hyperimmunized chicken egg yolk immunoglobulin is 
protective against rotavirus in animal models and humans (72-75).   
Even though passive transfer of immunoglobulins elicits safe immediate immune 
protection even in immunodeficient individuals, antibody production and 
purification procedures can be costly, and new methods for production and 
delivery of antibodies are in need.   
1.7.1. Bovine Colostrum Antibodies 
The cow can produce approximately 1-1.5 kg of immunoglobulins in the first 
few days after calving, making it an attractive platform for large-scale antibody 
production. Bovine colostrum-based immune milk derived antibodies, mainly 
IgG, have been used against gastrointestinal tract infections, including 
cryptosporidiosis, shigellosis, rotavirus, enterotoxigenic E. coli, and C. difficile 
infections (76, 77).  
Hyperimmune bovine colostrum (HBC) fed to rotavirus-infected calves (78) and 
infant mice (79-81) conferred a high level of protection, in a dose-dependent 
manner. Orally administered HBC antibodies are successfully used for treatment 
of rotavirus in children with rotavirus-induced diarrhea (82, 83). Remarkably, the 
most abundant immunoglobulin, colostrum IgG1, when given orally to mice, can 
resist proteolytic enzymes in the stomach (84), and retain high and stable activity 
in the small intestine for approximately 3.5 hours following administration (85). 
In humans, 50% of administered bovine antibodies resist digestion in the human 
upper gastrointestinal tract (86), suggesting that HBC antibodies can potentially 
be used as alternative, or complementary, treatment to rotavirus infections, 
especially in rotavirus vaccine risk groups.      
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1.7.2. Camelidae Family Heavy Chain Antibodies 
The novel discovery (1989) of Camelidae family heavy chain-only single-
domain antibodies (referred to as Nanobodies® or VHHs), started a new era for 
anti-viral therapy against rotavirus (79, 87-89), influenza-A (90, 91), poliovirus 
(92), HIV-1 (92, 93) and HBV (94). The VHH fragments are the smallest (12-15 
kDa in size) naturally available antigen binding domain known so far (95), with 
high acid and heat resistance, providing stability and functionality in vivo, and 
are able to reach cryptic epitopes that are inaccessible to conventional antibodies 
(Figure 5) (96). These properties make them suitable for therapy at mucosal 
sites such as the gastrointestinal tract where the acidic pH can limit the 
functionality of conventional antibodies.  
 
Figure 5. Structural features of different antibodies (97). Reprinted with the 
permission from Elsevier.  
Rotavirus specific VHH antibody fragments (named ARP1 and ARP3), were 
isolated from a llama VHH phage display library after immunizing the llama 
with RRV. ARP1 and ARP3 are the two VHHs that have been extensively 
studied in our group for therapy against rotavirus infections and were used 
successfully against rotavirus infections in an infant mouse model (88). Both 
fragments recognize polymeric VP6, which could be a conformational epitope, 
and are widely cross-reactive to different simian and human rotavirus strains, 
including the most prevalent ones (49). In a randomized placebo-controlled trial, 
ARP1 has been shown to be safe, and to reduce stool outcome in infants with 
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acute rotavirus diarrhea (98). Functional ARP1 fragments can be produced in 
yeast (88), Lactobacillus (87), and rice as a food-grade product (99).  
Multimerization of VHH fragments with different specificities can potentially 
increase cross-reaction capacity to several co-circulating genotypes of rotavirus, 
and reduce the appearance of escape mutants. An improved effect of 
combination of two or more monoclonal antibodies on virus neutralization has 
previously been demonstrated (100). In addition, fusion of 2-3 VHH fragments 
against viruses including respiratory syncytial virus (RSV), rabies and influenza 
H5N1 improves neutralization efficacy of single VHH fragments by 75-4000 
fold, by increasing avidity, mediating agglutination of viruses, and broadening 
neutralization of more serotypes, and some multimeric VHHs against RSV can 
reduce formation of viral escape mutants (90). 
1.8. LACTOBACILLUS-BASED THERAPIES: AN 
ANTIBODY DELIVERY SYSTEM 
Lactobacilli are Gram-positive lactic acid bacteria, which form a part of 
intestinal microbiota. From early 20
th
 century till date, many studies have shown 
their safety in the food industry, so they are referred to as “Generally Regarded 
as Safe (GRAS) microorganisms”. According to the report of FAO/WHO, 
probiotics are defined by: “live microorganisms which when administered in 
adequate amounts confer a health benefit on the host” (101). Several studies 
show host health benefits associated to use of certain Lactobacillus strains. 
Lactobacilli produce bacteriocins, short chain fatty acids, enzymes and vitamins 
which compete with pathogens for attachment to epithelial receptors, and induce 
anti-inflammatory and immunostimulatory responses (102). The best lactobacilli 
colonizers in gastrointestinal tract are L. gasseri, L. reuteri, L. casei and L. 
salivarius (103). L. rhamnosus GG, a well-studied probiotic strain in 
gastrointestinal tract infections, reduces duration of infantile diarrhea caused by 
rotavirus infections (79, 104, 105). The probiotic activity of L. rhamnosus GG is 
characterized by their colonization of the gastrointestinal tract, their ability to 
strengthen the intestinal barrier and to trigger innate and adaptive immune 
responses (106, 107). 
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Engineered lactobacilli for in situ delivery of antibodies or antibody fragments 
have been used successfully in treatment of rotavirus diarrhea (87, 108). The 
genetic modifications of Lactobacillus, in our studies, are based on expression of 
vectors comprising the promoter and signal peptide of the apf gene of L. 
crispatus M247, the gene encoding the antibody fragment or protein of interest, 
the gene encoding a tag for detection, and a sequence encoding the proteinase P 
surface protein (PrtP) of L. paracasei BL23 or L. rhamnosus GG for covalent 
anchoring on the cell surface. While lactobacilli producing surface-anchored 
VHH fragment reduced rotavirus diarrhea in a neonatal mouse model, the same 
antibody fragment was not protective when secreted by the same strain of 
lactobacilli due to a suboptimal production rate. Since the anchored antibody 
fragments are saturated on the surface of lactobacilli, they might inhibit rotavirus 
binding to the cell receptor, prior to cell infection.   
Multimeric display of anti-HIV antibodies on Caulobacter displaying protein G, 
markedly enhanced virus inhibition due to an increased avidity to HIV, as 
compared to soluble antibodies alone (109). In addition, surface anchored VHH 
dimer (ARP3-ARP1) produced by Lactobacillus, improves the therapeutic effect 
as compared to monovalent fragments and reduces rotavirus diarrhea in an infant 
mouse model (87).  
1.9. ANIMAL MODELS OF ROTAVIRUS INFECTION 
Several animal models including mouse, rat, rabbit, piglet, calf, lamb and baboon 
models are used in rotavirus infection and natural protection studies (51). 
However, the mouse and piglet models have been instrumental for infection, 
natural immunity, protection, and vaccine immunity studies.  
1.9.1. Mouse Model 
Mice at any age can be infected with rotavirus, and shed rotavirus particles in 
their stool. Although adult mice are asymptomatic, not showing clinical 
symptoms of rotavirus infection (infection-only model), young mice (less than 2 
weeks of age) provide both an infection and disease model (110). Both 
homologous and heterologous rotavirus strains, isolated from the same and 
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different species, respectively, are used for infection in mouse models. The lower 
replication rate of heterologous strains and absence of their horizontal spread to 
other uninoculated mice, have made them convenient models in several studies 
(111-113). In addition, the use of the simian rotavirus strain in mouse pups leads 
to physiopathological symptoms in pups identical to those produced by the 
corresponding murine strain (88). It has been shown that intestinal and serum 
anti-rotavirus IgA levels are correlated to protection in mice (51). Furthermore, 
administration of rotavirus specific antibodies or Lactobacillus expressing VHH 
antibody fragments neutralizes rotavirus efficiently, in a dose-dependent manner 
(79, 108).  
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2. AIMS 
2.1. GENERAL AIMS OF THE THESIS 
The main objectives of the thesis were to investigate host genetic factors leading 
to differential susceptibility to rotavirus infections and to develop antibody-based 
oral therapy against rotavirus infections. 
2.2. SPECIFIC AIMS 
Paper I. To unravel the role of TLR3 in rotavirus-specific IgG antibody 
responses in Swedish individuals with IgA deficiency as compared to Swedish 
healthy blood donors. 
Paper II. To investigate the involvement of human blood group antigens in 
rotavirus-specific IgG and neutralizing antibody responses in Swedish 
individuals with IgA deficiency and Swedish healthy blood donors.  
Paper III. To develop a combination therapy, consisting of engineered L. 
rhamnosus GG expressing surface anchored IgG binding domains of protein G, 
and soluble anti-rotavirus HBC antibodies.  
Paper IV. To generate L. paracasei BL23 expressing two rotavirus-specific 
llama VHH fragments (ARP1 and ARP3) in secreted and cell wall-anchored 
forms.  
Paper V. To evaluate the role of Fc-mediated anti-rotavirus activity, by fusing 
ARP1 to the Fc fragment of mouse IgG1 (Fc-ARP1).  
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3. MATERIALS AND METHODS 
3.1. SERUM SAMPLES 
Serum samples from Swedish IgA deficient and Swedish healthy blood donors 
were used in Paper I and Paper II. The regional ethical review board in 
Stockholm, Sweden approved these aforementioned studies with the following 
permits: Dnr 2011/69-31/3 and Dnr 2013/1176-31/1.  
In Paper I, serum samples from 783 Swedish IgA-deficient individuals and 1009 
anonymous healthy blood donors were collected for the TLR3 genotyping 
analysis. 180 IgA-deficient and 198 healthy individuals were included in the 
rotavirus-specific IgG antibody titer measurements.  
In Paper II, serum samples from 767 Swedish IgA-deficient individuals and 
1008 anonymous healthy blood donors were collected for the FUT2 and FUT3 
genotyping analysis. Among all individuals, the number of individuals included 
in rotavirus-specific IgG antibody titer assessment was narrowed down to 378 
individuals (180 IgA-deficient and 198 healthy individuals). In addition, for 
evaluation of serum neutralizing antibody responses, the serum samples from 41 
IgA-deficient and 48 healthy individuals were used in this study.  
3.2. GENOTYPING    
SNP genotyping of the TLR3 (rs3775291 and rs5743305) in Paper I, and FUT2 
(rs601338) and FUT3 (rs28362459, rs3894326, rs812936 and rs778986) genes 
in Paper II were performed at the Mutation Analysis Facility (MAF) at 
Karolinska Institutet, Stockholm, Sweden. SEQUENOM platform was used 
based on a matrix assisted laser desorption ionization-time of flight (MALDI-
TOF) analysis.  
3.3. NEUTRALIZATION ASSAY 
The neutralization of rotavirus strains Wa and ST3 by serum samples was in 
MA104 cells by the immunoperoxidase assay in Paper II. The serum dilution, 
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leading to higher than 60 % reduction in the number of stained infected cells was 
considered to be the neutralizing antibody titer.  
3.4. BACTERIAL STRAINS  
L. rhamnosus GG, used in Paper III, was provided by Prof. Marika Mikelsaar, 
University of Tartu, Estonia. L. paracasei BL23 (previously referred to as L. 
casei 393, or pLZ15
-
), used in Paper IV, was obtained from Dr. Peter Pouwels, 
TNO Institute, the Netherlands. Lactobacillus strains were grown in MRS broth 
(Difco, Sparks, MD) in standing aerobiosis conditions at 37°C. MRS medium 
was supplemented with 5 microgram per milliliter of erythromycin for 
Lactobacillus transformants.  
3.5. ROTAVIRUS STRAINS 
The simian rotavirus strain RRV was used in all studies. In Paper I and II, it was 
used to evaluate the rotavirus-specific IgG responses. In Paper III and V, RRV 
strain was used for viral challenge in neonatal mouse pups. Furthermore, RRV 
was used in analysis of virus binding in Paper III-V. Another simian rotavirus 
strain, SA11, was used in virus binding assay in Paper IV. Human rotavirus 
strains Wa and ST3 were used for neutralization studies in Paper II. In addition 
other human rotavirus strains including Wa, ST3, 69M, Va70, F45 and DS1 
were used in Paper IV.   
The rotavirus strains were grown, harvested from mammalian cells, and the viral 
titers were calculated as mentioned previously (114, 115). The RRV strain was 
kindly provided by Ass. Prof. Kari Johansen, Department of Microbiology, 
Tumor and Cell Biology, Karolinska Institute, Stockholm, Sweden. Additionally, 
Wa, ST3, 69M, Va70, F45, DS1 and SA11 were kindly supplied by Prof. Miren 
Iturriza-Gómara, Enteric Virus Unit, Centre for Infections, Health Protection 
Agency, London, UK. 
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3.6. GENERATION OF ARPS: ARP1 AND ARP3 
Immunization of Ilamas with RRV strain MMU18006, P5B, G3, followed by 
selection of ARP1 and ARP3 has previously been described (88). ARP1 was 
previously referred to as 2B10 (88) or VHH1 (108). ARP1 and ARP3 produced 
in Saccharomyces cerevisae, were purified using ion exchange chromatography 
by BAC BV (The Netherlands). The purity was found to be higher than 95 %. 
The ARP1 was used in Paper IV and V, and ARP3 in Paper IV. 
3.7. HYPERIMMUNE BOVINE COLOSTRUM ANTIBODY 
PREPARATION 
The HBC, used in Paper III, was produced by vaccination of pregnant cows in a 
Swiss dairy farm with human strains of rotavirus (Wa, RV3, RV5 and ST3) 
representing the serotypes of 1 to 4 (116). The freeze-dried HBC concentrate is 
composed of 28,1% IgG, 6,1% IgA and 2,2% IgM antibodies. The HBC 
preparation was kindly provided by Dr. Harald Brüssow, Nestlé Research 
Center, Nutrition and Health Department/Food and Health Microbiology, 
Lausanne, Switzerland.  
3.8. CLONING IN LACTOBACILLUS 
In Paper III, the IgG binding domains of protein G of Streptococcus sp. Group G 
was cloned in pAF900 plasmid and expressed on the surface of L. rhamnosus 
GG.  
In Paper IV, three different co- expression cassettes were constructed where the 
two ARP fragments  (ARP1 and ARP3) can both be secreted in the medium, one 
secreted and the other anchored on the cell surface, or both covalently anchored 
on the cell surface. The vectors were transformed into L. paracasei BL23.  
3.9. EXPRESSION AND PURIFICATION OF FC-ARP1 AND 
FC-ARP1N434D 
In Paper V, the gene encoding the Fc fragment of mouse IgG1 (hinge region and 
CH2-CH3 domains) was fused to the gene encoding ARP1. Site-directed 
mutagenesis was used as a service of GenScript, to generate a single-point 
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mutation in the Fc-ARP1 gene replacing the asparagine corresponding to the 
position 434 of the original heavy chain sequence with aspartic acid (N434D). 
This mutation was previously shown to markedly impair neutralization of 
adenovirus in vitro, by inhibiting IgG Fc binding to TRIM21. Fc-ARP1 and Fc-
ARP1N434D were transiently expressed in HEK 293-6E cells and purified 
(GenScript (Piscataway, NJ). 
3.10. ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA) 
This method was used for detection of RRV-specific antibody responses in 
Paper I and II, for quantification of HBC IgG antibodies in Paper III, for 
evaluation of binding of antibody and antibody fragments to rotavirus in Paper 
IV and V.  
3.11. EXPRESSION ANALYSIS  
The production of surface-anchored IgG binding domains of protein G (GB1-3) 
by L. rhamnosus GG in Paper III, and co-expressed ARP1 and ARP3 fragments 
in secreted and surface-anchored forms by L. paracasei BL23 in Paper IV were 
determined by Western blot. In Paper V, llama conventional antibody-like 
ARP1-Fc antibody and its derivatives were detected both in Western blot and 
SDS-PAGE gel stained with Coomassie brilliant blue.  
3.12. SCANNING ELECTRON MICROSCOPY (SEM) 
The L. rhamnosus GG cells were incubated with PBS only (-ive control) or a 
mix of RRV (10
8
 ffu/ml) and anti-rotavirus HBC (10 µg/ml) in Paper III. The 
cells were fixed with 0.1 ml 2 % glutaraldehyde, and the samples were 
consecutively analyzed by SEM in the electron microscopy unit (EMil) at the 
Karolinska University Hospital Huddinge, Sweden. 
3.13. FLOW CYTOMETRY ANALYSIS 
Flow cytometry analysis was used in Paper III and IV for detection of surface-
displayed antibody fragments and antibodies on the surface of lactobacilli, and to 
determine the binding of lactobacilli displaying antibody and antibody fragments 
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to rotavirus. Following incubations with antibodies and/or rotavirus, engineered 
Lactobacillus cells were pelleted down and washed prior to fixation with 0.5 % 
paraformaldehyde (PFA). Cell staining data were acquired by FACS Calibur 
machine (Becton, Dickinson and Company), and analyzed in FlowJo software 
(TreeStar, Ashland, OR).  
3.14. NEONATAL MOUSE MODEL OF ROTAVIRUS 
DIARRHEA 
All the animal experiments, in Paper III and V, were approved by the local 
ethical committee of the Karolinska Institutet at Karolinska University Hospital 
Huddinge, Sweden. An infant mouse model of heterologous infection with 
rhesus rotavirus (RRV) was used to evaluate the effect of distinct prophylactic 
treatments in protection against rotavirus induced diarrhea. Fourteen day 
pregnant, rotavirus-free certified, wild-type BALB/c mice were purchased from 
Charles River Lab, Germany. The experiments were started with 4 day old pups 
that were randomly distributed in groups of 7–8 pups per dam. Antibodies or 
engineered lactobacilli were administered orally, once daily in 10 µl volume, 
starting from one day before the infection (day -1), until the last day of the 
experiment (day 4, in Paper III, and day 5, in Paper V). On the infection day 
(day 0), each mouse pup was infected once with RRV in a 10 µl volume, two 
hours after the treatment with antibodies or lactobacilli.  
Diarrhea was recorded from the start until the last day of the experiment. 
Severity of diarrhea was scored based on the consistency of stool outcome. On 
the last day of the experiment, sections of small intestine were collected from 
euthanized mouse pups for subsequent real-time PCR analysis.  
3.15. QUANTITATIVE REAL-TIME PCR (RT-PCR) 
All small intestinal samples were homogenized using the TissueLyser MM301 
system (Retsch GmbH, Haan, Germany). RNeasy RNA isolation kit (Qiagen 
GmbH) was used for total RNA isolation. In the process of RNA purification, 
on-column DNA digestion was performed using a RNase-free DNase set 
(Qiagen GmbH). cDNA was synthesized from 1 µg of total RNA using a first-
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strand cDNA synthesis kit (GE Healthcare) based on manufacturers` protocol. 
The SyBr Green detection system was used in RT-PCR analysis.  
The RRV VP7 viral mRNA was amplified to evaluate the viral load in Paper III 
and V, using a pair of specific primers: 5`-GCAATGTCCAAAAGATCACG-3` 
and 5`-GGTCACATCATACATTTCTATCCAA-3`.  
Both IFN-β and TRIM21 gene expression analysis were performed in Paper V.    
For quantification of interferon beta (IFN-β) expression levels, the following 
primer pairs were used: 5`-AAGAGTTACACTGCCTTTGCCATC-3` and 5`-
CACTGTCTGCTGGTGGAGTTCATC-3`. The assessment of the TRIM21 gene 
expression was performed using the primer pairs: 5`-
CTGCAGGAGCTGATCTCAG-3` and 5`-TGTCCTCAGCATCTTCTTC-3`.          
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4. RESULTS 
4.1. PAPER I 
Individuals with IgA deficiency showed significantly elevated serum levels of 
rotavirus-specific IgG, suggesting a compensatory role of IgG in rotavirus 
infection and a protraction of rotaviral persistence/shedding after infection, 
although the disease is ultimately resolved. Upon the recent findings of low 
TLR3 expression being involved in susceptibility to rotavirus infections (36), we 
investigated rotavirus-specific IgG antibody responses from individuals (IgA 
competent or deficient) with two well-characterized and highly damaging TLR3 
single nucleotide polymorphisms (rs3775291 and rs5743305). We concluded 
that these two polymorphisms were associated with elevated IgG titers in IgA 
deficient, but not in IgA competent individuals.   
4.2. PAPER II    
The histo-blood group antigens were previously shown to serve as receptors for 
rotavirus VP8 on the host cells (10, 24). In Paper II, we have studied the effect 
of inactivating mutations in the FUT2 (rs601338) and FUT3 genes (rs28362459, 
rs3894326, rs812936 and rs778986) on rotavirus-specific serum IgG antibody 
responses and neutralizing antibody responses to rotavirus Wa (P[8]) and ST3 
(P[6]) strains in Swedish individuals (IgA competent or deficient). The rotavirus 
specific serum IgG levels and neutralizing antibody titers to the Wa strain (P[8]) 
of rotavirus were significantly higher in secretors than non-secretors (P < 0.001), 
suggesting that secretors are more prone to P[8] rotavirus infections as compared 
to non-secretor individuals, independent of their IgA status. We thus suggest that 
distinct protection mechanisms against rotavirus might be engaged in IgA 
competent healthy controls, FUT2 mediated, and in IgA deficient individuals, 
both TLR3 and FUT2 mediated.  
4.3. PAPER III 
In this study, L. rhamnosus GG, a well-known probiotic strain of Lactobacillus, 
was engineered to produce surface-anchored IgG-binding domains of protein G 
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which capture rotavirus-specific hyperimmune bovine colostrum (HBC) 
antibodies for protection against rotavirus. The combination therapy with 
engineered L. rhamnosus GG (PG3) and HBC was significantly more effective 
in reducing the prevalence, severity, and duration of diarrhea in a mouse pup 
model of RRV infection, in comparison to HBC alone or a combination of wild-
type L. rhamnosus GG and HBC. This combination therapy can reduce the 
treatment costs, and the antibody capturing platform can further be applied to 
treat other gastrointestinal pathogens.  
4.4. PAPER IV 
In Paper IV, we have developed vectors including two expression cassettes in 
tandem for co-expression of two rotavirus- specific llama heavy chain variable 
fragment (VHH): ARP1 and ARP3. Engineered L. paracasei BL23 was shown 
to produce two antibody fragments (secreted or anchored), and bind to a broad 
range of rotavirus serotypes (including the human rotavirus strains 69M, Va70, 
F45, DS1, Wa and ST3 and simian rotavirus strains RRV and SA11) in vitro. 
This Lactobacillus-based co-expression platform might help reducing 
appearance of escape mutants, as the two VHH fragments are targeting distinct 
epitopes of rotavirus, and be used to produce other VHHs or proteins to target 
other gastrointestinal pathogens in future.    
4.5. PAPER V 
In this study, we have fused the mouse IgG1 Fc to ARP1 to improve the 
protective capacity of ARP1 in vivo. We have shown that the Fc-ARP1 fusion 
protein confers a significantly increased protection against rotavirus in a neonatal 
mouse model of rotavirus-induced diarrhea by reducing the prevalence, duration 
and severity of diarrhea and the viral load in small intestines of mouse pups. We 
suggest that the Fc part of immunoglobulins might be engaged in intracellular 
neutralization by involving Fc receptor activation.  
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5. DISCUSSION  
Rotavirus infections affect young children all around the globe. The increase in 
severity of rotavirus induced diarrhea and susceptibility to rotavirus infections 
might be attributed to several factors (117)  including malnutrition, low birth 
weight, cool season, dry climate, poor hygiene conditions, healthcare associated 
infections (outbreaks in neonatal intensive care units or hospital visits), 
infections with different co-circulating rotavirus genotypes, co-infections with 
other pathogens (HIV, E. coli, and Salmonella, etc.), immunodeficiency (X-
linked agammaglobulinemia (XLA), common variable immunodeficiency 
(CVID), severe combined immunodeficiency (SCID), and IgA deficiency), and 
genetic factors (mutations in genes of TLR signaling pathway, and in FUT2 and 
FUT3 genes involved in the synthesis of HBGAs).   
The two rotavirus vaccines, Rotarix
TM
 and Rotateq
TM
 are currently licensed for 
protection against rotavirus in infants. While rotavirus induced diarrhea might be 
referred to as a vaccine preventable disease in certain parts of the world (more 
than 85 % efficacy in countries in Europe, South and North America, and 
Australia), the vaccine efficacy is relatively low (40-60 %) in several other 
countries in Asia and Africa, where rotavirus is the major pediatric pathogen 
causing high mortality (accounts for a cumulative mortality of 85 %) (60, 61, 
118). In addition to low vaccine efficacy issues in the most affected populations, 
the vaccine companies have notified plausible vaccine-associated 
contraindications for use in infants with XLA, CVID and SCID. Interestingly, 
immunization protocols in some countries suggest consultation with an 
immunologist for individuals with IgAD before vaccination. However, the fact 
that vaccination starts at the age of 6-12 (Rotateq
TM
), or 6-24 weeks (Rotarix
TM
) 
means that infants with immunodeficiency are not diagnosed prior to vaccination 
(median age for diagnosis of SCID: 4-7 months), putting the immunosuppressed 
infants with no family history of immunodeficiency into great danger for severe 
post-vaccination outcomes including acute diarrhea, shedding vaccine-acquired 
rotavirus strains, co-infection with pathogens including E. coli and Salmonella, 
and extended rotavirus shedding (up to 11 months) (67). Furthermore, there is 
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inadequate information on vaccine safety and efficacy in undiagnosed HIV 
infected children in developing countries, which also raises concerns for risk of 
developing post-vaccine symptoms.   
The chronic wild-type and vaccine-acquired rotavirus infections in infants with 
SCID might be detrimental, causing chronic diarrhea, failure to thrive and early 
onset of infections. Early diagnosis of the disease and hematopoietic stem cell 
transplantation before onset of severe infections are therefore required (64, 119). 
The affected immunocomprimized infants might also be the ones suffering from 
the lack of specific maternally derived secretory IgA antibodies in breast milk 
directed against the emerging serotypes of rotavirus (120). In addition, infants 
with primary immunodeficiency in the TLR signaling pathways have also been 
reported to suffer from chronic infections (121). Deficiencies in certain TLR-
pathways, such as MyD88-IRAK4 and TLR3-Unc93b-TRAF3, confer 
predisposition to pyogenic bacteria and HSV encephalitis, respectively (122, 
123), which might be due to reduced or impaired IFN production (124). Even 
though adults with compromised TLR signaling show no severe clinical 
outcomes, it might be different for children. More than 100 polymorphisms have 
been identified in the TLR3 gene so far, some of which have functional 
implications due to the lack of TLR3 expression and reduced functionality 
(rs5743305 and rs3775291), such as impaired IFN-/-β and IFN-λ production. 
Patients with TLR3 deficiency have been shown to be susceptible to HSV. In 
Paper I, it has been shown that two polymorphisms (rs5743305 and rs3775291), 
causing impaired or reduced TLR3 expression or function, might also be a factor 
for susceptibility to rotavirus infection in immunodeficient, but not in 
immunocompetent individuals. As previously shown (44), elevated anti-rotavirus 
IgG antibody titers was shown in the IgA deficient as compared to the IgA-
sufficient group. To determine the immunological basis for the elevated 
rotavirus-specific titers in individuals with IgAD, intragroup differences in IgAD 
individuals were analyzed. Interestingly, no change in anti-rotavirus IgG 
response was detected in IgA competent individuals with impaired TLR3 gene. 
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However, individuals with combined IgA and TLR3 deficiency were presented 
with increased specific IgG titers as compared to individuals with impaired 
TLR3 only, suggesting an increased susceptibility to severe, chronic and/or 
recurrent rotavirus infection in individuals with both of these defects (44). 
Reduced TLR3 expression in neonatal mice has previously been shown to be 
associated with rotavirus susceptibility by Pott et al., suggesting that a relatively 
under-developed immune system, due to young age or mutations, make 
individuals vulnerable to infections. Although, complete lack of TLR3 signaling 
can cause severe clinical outcomes in some individuals, there is no information 
about the impact of these polymorphisms at the population level.      
The genetic variations at the population level might also influence susceptibility 
to rotavirus infections. Until recently, low vaccine responses in the developing 
world has been associated with a higher incidence of concomitant infections, 
larger rotavirus strain diversity, and poor health status. Recent in vitro studies 
have suggested that HBGAs (H type 1 and Lewis antigens) are putative receptors 
for rotavirus VP8* (10, 16, 17). Therefore, we have studied the effect of 
inactivating polymorphisms in the FUT2 (rs601338) and FUT3 genes 
(rs28362459, rs3894326, rs812936 and rs778986), contributing to secretor and 
Lewis phenotypes, respectively, in the antibody response to rotavirus in Swedish 
individuals (Paper II). The rotavirus specific serum IgG titers and neutralizing 
antibody levels to the Wa strain (P[8]) of rotavirus were significantly higher in 
secretors (individuals with at least one functional FUT2 gene) than in non-
secretors (individuals with homozygous nonsense mutation in the FUT2 gene), 
suggesting that secretors are more prone to rotavirus (P[8]) infections as 
compared to non-secretors (Paper II). This finding implies that the Lewis 
negative individuals, being approximately 22-32 % in Africa (21, 23), are most 
likely resistant to P[8] virus infection. However, both vaccine formulations are 
based on rotavirus with P[8] genotype, and meant to resolve rotavirus infections 
especially in the developing world including Africa. The resistance to P[8] 
rotavirus infections through non-secretor phenotype might clarify the reduction 
in efficacy of current P[8]-based vaccines used in the developing world, more 
particularly in sub-Saharan Africa. The reason of high efficacy of vaccines used 
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in developed part of the world could be because both the vaccine strain and 
circulating rotavirus strain match. Furthermore, the majority of the population is 
composed of secretors, whom can be infected with either of the wild-type and 
vaccine P[8] virus strains. Interestingly, rotavirus P[6] infections comprise 
approximately one third of all the characterized P types in Africa (7), suggesting 
that vaccines should be tailored according to genetic needs of each population: a 
P[6]-based vaccine might serve as an efficient vaccine therapy in Africa. 
Furthermore, alternative or complementary effective prophylactic and 
therapeutic passive immunotherapy regimens, providing a more rapid response 
against rotavirus infections are warranted.    
Passive immunotherapy has been used in prevention and treatment of many 
diseases, especially in fields where antimicrobial treatments are inadequate 
(125). The importance of passive immunotherapy was recognized in the early 
1890s in the area of infectious diseases, by showing that antibodies conferred 
protection against bacteria and toxins, which allowed use of serum derived from 
immunized animals (sheep or horse) for treatment of infectious diseases (126). 
Later on, serum therapy was abandoned due to hypersensitivity reactions against 
animal proteins, and replaced by antimicrobials and antibiotics. However, raised 
awareness in the generation and spread of drug-resistant microorganisms in the 
environment, formation of newly emerging microorganisms and impractical use 
of antimicrobial treatments in immunosuppressed individuals focused attention 
back to antibody-based immunotherapy, a safe and immediate course of action 
against infectious diseases.   
The traditional method of generating polyclonal antibodies in a host is by 
injection of the antigen of interest and subsequent collection of serum, 
containing specific antibodies. Polyclonal antibodies, mainly IgG, recognize 
multiple epitopes on an antigen, which might enhance detection and broaden the 
applicability of a given therapy. Thus, the fact that colostrum from selected 
species contains a high concentration of antibodies for protection of newborns 
from diseases, another polyclonal antibody production method was introduced. 
Pregnant cows challenged with an antigen of interest can produce large amounts 
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of specific antibodies, comprised mostly of IgG. The bovine colostrum IgG 
antibodies, derived from hyperimmunized cows, have previously been 
successfully used for protection in rotavirus-infected children in large field 
studies (127).  
Probiotic bacteria represent an attractive delivery system of proteins and 
antibody fragments in the gastrointestinal tract. They colonize the 
gastrointestinal tract, ensuring the stability and stable expression or display of 
specific proteins at the site of gastrointestinal infections. Use of probiotic 
bacteria contained in a commercial product, BioGaia® Probiotic drops 
(Ewopharma AG, Bulgaria), is free from side effects if administered to healthy 
infants, children and adults, as well as immunodeficient adults, thus lactobacilli-
mediated therapy might be applied to individuals at any age and with almost any 
immunologic background, including individuals with immunodeficiency. L. 
rhamnosus GG is a well-studied probiotic strain of lactic acid bacteria in 
gastrointestinal tract infections. When administered to hospitalized children with 
diarrhea, the prevalence of diarrhea and symptomatic rotavirus infection were 
markedly reduced (128, 129). Oral L. rhamnosus GG therapy also reduced the 
severity, duration and prevalence of infantile diarrhea caused by rotavirus RRV 
infections in a neonatal mouse model (79). L. rhamnosus GG was previously 
combined with exogenously delivered soluble HBC antibodies in a neonatal 
mouse pup model. When combined with L. rhamnosus GG, a 10-fold lower dose 
of HBC antibodies (10 μg) significantly reduced all measures of diarrhea similar 
to soluble HBC alone (100 μg) (79). The probiotic bacteria could potentially be 
involved in induction of innate immunity (secretion of cytokines) and production 
of mucosal IgA antibodies, which might inhibit the viral replication. In Paper III, 
L. rhamnosus GG was engineered to produce surface-anchored IgG-binding 
domains of protein G (PG3), which capture exogenous rotavirus-specific 
hyperimmune bovine colostrum (HBC) antibodies, consisting mostly of IgG 
antibodies, for protection against rotavirus. The new combination therapy 
reduces the effective dose of HBC by 10 to 100 fold, and the effective L. 
rhamnosus GG dose by 10 fold, and may thus decrease treatment costs. The 
rotavirus specific HBC antibodies might neutralize virus in bacteria-displayed or 
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soluble form through distinct mechanisms. The dense multimeric display of IgG 
by PG3 might promote a higher avidity in binding and stronger agglutination 
compared to the same amount of soluble antibody. This might result in enhanced 
blocking and reduce infection of mucosal cells. The soluble antibodies might 
also contribute to virus neutralization by binding to free rotaviral particles or to 
available epitopes of rotavirus, which are stabilized by PG3. Free HBC-IgG 
might also bind to the mouse neonatal Fc receptors (FcRn) (130) and neutralize 
virus intracellularly. PG3 would also be expected to extend the half-life of the 
HBC antibodies in the gastrointestinal tract.  
Antibody-based therapy has a long history of reliable use, however high cost 
incurred by production of polyclonal antibodies have re-directed the research to 
focus on exploration of new highly efficient antibodies and antibody fragments 
derived from different sources (95, 96, 131, 132). The discovery of VHH 
antibody fragments is one of the novel advances in antibody therapy. VHHs are 
naturally available, thermostable, safe and small antibody fragments derived 
from Camelidae heavy chain antibodies. VHH antibody libraries have been 
generated from llamas immunized with rotavirus and shown to be cross-reactive 
against various G and P types. Rotavirus specific VHHs, including ARP1 and 
ARP3, were selected in low pH and in the presence of pepsin, providing stability 
during passage from the stomach to the gastrointestinal tract. Both ARP1 and 
ARP3 recognize dimeric VP6 protein of rotavirus (49), suggesting that they are 
most likely detecting structurally available, cryptic epitopes of virus, which 
might not be recognizable to conventional antibodies. Due to the small size, the 
rotavirus specific VHH antibody fragments can be produced by several 
organisms including yeast, lactic acid bacteria and mammalian cells, and be 
delivered as a food-grade product (expression in rice). Yeast produced VHH 
fragments (ARP1) were found to be safe in a Phase III clinical trial in children 
(98), and the rotavirus specific activity of rice-ARP1 did not change when boiled 
for 5 minutes (133), suggesting a high stability when passing through the harsh 
conditions of the stomach in vivo. The reasons for expressing and delivering 
antibodies or antibody fragments in organisms, involving probiotic lactic acid 
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bacteria, are to provide stability and improved activity, and reduce the 
production and storage expenses of the antibody therapy.  
Another strain of Lactobacillus, L. paracasei BL23, was used to express VHH 
antibody fragments (Paper IV). Engineered lactobacilli producing surface-
anchored ARP1 and ARP3 were previously generated and shown to be effective 
in a mouse model of rotavirus infection. The production of one VHH fragment 
targeting a single epitope has limitations due to reduced cross-reactivity to 
circulating viral serotypes and potentially emerging viral escape mutants. In 
contrast, targeting multiple epitopes might improve the efficacy due to an 
increased activity towards a broad range of viral serotypes and a less likelihood 
of accumulating viral escape mutants. The aim of this study was to generate co-
expression vectors for the production of two rotavirus-specific ARP1 and ARP3, 
which might increase the avidity for rotavirus binding and aggregation due to 
binding to distinct epitopes. Additionally, if the virus acquires mutation on the 
binding site of an antibody fragment, the other antibody fragment will retain its 
activity against the virus. ARP1 and ARP3 were produced in vectors by two 
different expression cassettes: one allowing secretion, the other surface-
anchoring of antibody fragments. Secreted VHH(s) might neutralize the virus 
outside the cell by preventing cell attachment, as well as inside the cell if it 
enters bound to rotavirus (due to its small size). However, anchored VHHs can 
saturate the surface of bacteria (6000 molecules/bacterium) (134), and might 
induce a stronger aggregation and neutralization response. It was previously 
shown in mice that L. paracasei BL23 producing anchored ARP1 confer 
stronger reduction in rotavirus diarrhea than the secreted version (108). 
Expression of distinct rotavirus specific fragments in Lactobacillus could 
increase the chance of neutralization through binding to different epitopes of the 
virus. The Paper IV has shown for the first time that ARP1 and ARP3, produced 
by engineered lactobacilli and directed against different epitope specificity, can 
bind strongly to several human and simian rotavirus strains from distinct 
genotypes, suggesting a broader cross-reactivity to many G/P combinations, thus 
representing an alternative therapy for individuals in the developing world who 
are infected mostly with rare rotavirus genotypes.  
  33 
In addition to neutralizing activity outside the cells, Fc-mediated responses can 
be induced for an improved intracellular neutralization, as suggested by Paper V. 
The ARP1 fragment, which was extensively studied in our previous studies, was 
fused to a mouse IgG1 Fc to evaluate the in vivo effect of Fc and potential 
involvement of Fc effector functions. When fused to Fc, the anti-rotavirus effect 
of ARP1 was dramatically increased, not related to bivalency of ARP1, as 
bivalent ARP1 did not show any sign of protection against rotavirus diarrhea in 
mouse pups at the tested concentrations (provided that equal ARP1 molecules 
are given in each treatment). The N434F mutation was recently described to 
dramatically reduce the in vitro binding of IgG Fc to TRIM21, a cytosolic Fc 
receptor (135). This mutation was introduced into the Fc of the Fc-ARP1 fusion 
protein in Paper V. The infant mice treated with mutated FcN434F-ARP1 showed 
a slightly lower protection against rotavirus than the mice treated with Fc-ARP1, 
suggesting either TRIM21 might not be involved in protection against rotavirus 
in a greater extent or the mutation did not function as expected based on in vitro 
studies. A pull-down assay will be performed in the future to evaluate the 
binding of Fc-ARP1 and mutated FcN434F-ARP1 to TRIM21.  
In addition to TRIM21, other Fc receptors (FcRn and FcγR) might also play role 
in intracellular rotavirus neutralization. Even though they also detect antibody-
virus complex through the Fc part of the antibody, their binding site is not 
exactly the same as the TRIM21 receptor binding site, which might explain why 
the mutation did not greatly affect the in vivo response. Although the mechanism 
by which the Fc receptor can greatly improve protection is not known, a clear 
Fc-mediated response initiated with the Fc part of llama-like antibody (Fc-
ARP1) was shown in a neonatal mouse model of rotavirus diarrhea. In order to 
activate different cellular responses for an enhanced anti-rotavirus response, 
more than one therapy approach might be considered for use in future.  
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6. FUTURE PROSPECTIVES 
The development of Lactobacillus based delivery of antibody and antibody 
fragments can be useful during an epidemic of rotavirus infections in developing 
countries or in hospital acquired infections. This treatment would particularly be 
useful for individuals who do not fit in the recruitment criteria for vaccine 
therapy, or simply are not responding to vaccines well.   
For large-scale production of engineered Lactobacillus, the bacteria can be 
grown in fermentors, and stored and distributed in several forms of food: 
yoghurt, milk powder, etc. To avoid using antibiotic resistance markers and 
dissemination of genes, the gene encoding the specific antibody fragment can be 
inserted in the genome of Lactobacillus as previously described (134). In 
preparation for a safety clinical trial, the ARP1 encoding gene was recently 
inserted into the genome of L. rhamnosus GG by site specific recombination, and 
the thymidine gene was deleted, allowing conditional growth of bacteria. This 
Lactobacillus delivery system, if safe in Phase I, and safe and efficient in Phase 
II-III clinical trials, can be used to produce multivalent ARPs for an improved 
protection against rotavirus. The advantages of using genetically modified 
lactobacilli are to provide a treatment combining safety, low cost of production, 
long term stable conservation in non-refrigerated conditions, rapid distribution, 
easy administration and adequate long term protection.  
Future therapeutic strategies should probably trigger different modes of immune 
action in. The gene encoding the sequence of protein G could be integrated into 
the genome of L. rhamnosus GG. This modified Lactobacillus can be further 
combined with HBC-IgG or a mixture of Fc-ARP1 and Fc-ARP3. In addition, 
even though the full size Fc-ARP1 antibody cannot be expressed by lactobacilli, 
ARP1 could instead be fused to a VHH against the FcRn or FcγR in order to 
improve intracellular neutralization. This dimeric VHH could subsequently be 
expressed as a secreted protein in lactobacilli. The efficiency in transcytosis 
might be further improved through receptor clustering by using multivalent 
VHHs against the receptor. VHHs targeting the polymeric immunoglobulin 
receptor were recently used to deliver therapeutic molecules from basolateral to 
  35 
apical side of mammalian cells in vitro (136), showing the potential of VHHs as 
carriers across epithelia.  
Alternatively, engineered lactobacilli delivering multimeric VHHs against a 
panel of enteric pathogens can be used for simultaneous treatment against 
several gastrointestinal microbes threatening the lives of children in the 
developing world. The children with a family history of immunodeficiency, at 
risk to develop chronic rotavirus infections, can be provided with engineered 
lactobacilli producing cytokines, involved in clearance of rotavirus (137). 
In the future, personalized therapy will be provided for each individual. Neonatal 
screening for severe forms of immunodeficiency, introduced in selected states in 
the USA (138), may provide early diagnosis and allow individualized therapy 
prior to rotavirus vaccination.  
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7. CONCLUSIONS  
 
Paper I. Polymorphisms in TLR3 gene are associated with increased levels 
of rotavirus-specific IgG antibody responses in individuals with IgA 
deficiency, suggesting an increased susceptibility to rotavirus infection in 
individuals with both TLR3 and IgA deficiency. 
 
Paper II. Individuals with intact secretor (FUT2) gene have elevated 
rotavirus-specific IgG and neutralizing antibody responses, independent of 
their IgA status, suggesting that human blood group antigens serve as 
susceptibility factors to rotavirus infections.  
 
Paper III. A combination therapy, consisting of engineered L. rhamnosus 
GG expressing surface anchored IgG binding domains of protein G, and 
soluble anti-rotavirus HBC antibodies markedly reduced the prevalence, 
severity and duration of diarrhea in a mouse pup model of RRV infection. 
 
Paper IV. L. paracasei BL23 co-expressing rotavirus-specific llama VHH 
fragments (ARP1 and ARP3) in secreted and cell wall-anchored forms, bind 
to variable human and simian rotavirus strains with a broad range of 
genotypes.  
 
Paper V. Fusing ARP1 to the Fc fragment of mouse IgG1 (Fc-ARP1) 
increases Fc-mediated neutralization of rotavirus in a neonatal mouse model.  
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